Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Washington University School of Medicine
Study ID
NCT06812429
Phase
EARLY_PHASE1
Status
Completed

Conditions

  • Inflammation

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Dapagliflozin (DAPA) — DRUG
    Participants will receive 10mg of Dapagliflozin per day for three days.

Study Details

The research aims to understand how a specific type of medication called Sodium-glucose co-transporter 2 (SGLT2) inhibitors affect cardiorenal inflammation.

Key Dates

Start date
May 8, 2024
Status verified
Jan 2026
Primary completion
Apr 5, 2025
Completion
Apr 5, 2025

Study Design

Enrollment
6 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Dapagliflozin group
    Participants in this arm receive dapagliflozin 10mg for three days.

Primary Outcome Measure

Change from baseline in the markers of Inflammation at three days [ Time Frame: From enrollment to the end of treatment at 3 days. ]

Locations (1)

FacilityCityStateZIPSite coordinators
Washington UniversitySt LouisMissouri63110-

Find similar trials in St Louis, MO

By research site
Washington University· St Louis, MO

Related Studies